Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients

Table 3

Upstream regulators predicted by IPA in the peripheral blood cells of breast cancer patients compared with healthy donors.

Upstream regulator	Fold change	Molecule type	Predicted activation state	-score	value of overlap	Target molecules in dataset
BC versus CTR
PTGS2	5.764	Enzyme	Activated	2.322		AREG/AREGB, CCL3L1/CCL3L3, CCL4, CXCL14, CXCR2, CXCR4, DUSP1, EGR1, FOS, IL-8, ITGA6, NBN, NR4A2, PTGS2
TREM1	2.051	Transmembrane receptor	Activated	2.685		AREG/AREGB, CCL3, CEBPB, CXCL1, CXCL2, CXCR4, EGR1, EGR2, EGR3, IL-8, NR4A2, PTGS2, RGS1, SFMBT2
ER+PR+HER− versus CTR
F7	−2.303	Peptidase	Activated	2.736		CXCL2, EGR1, FOS, IER2, IL-8, JAG1, KLF5, ZFP36
AREG	4.422	Growth factor	Activated	2.395		AREG/AREGB, CXCR4, EGR1, FOS, NPPC, PTGS2
ER−PR−HER2− versus CTR
AREG	2.803	Growth factor	Activated	2.407		AREG/AREGB, CXCR4, EGR1, FOS, PLAU, PTGS2